The era of in vivo T cell engineering

Gustavo Campos Ramos; Michael Hudecek

doi:10.1016/j.medj.2022.01.012

The era of in vivo T cell engineering

Med. 2022 Feb 11;3(2):85-86. doi: 10.1016/j.medj.2022.01.012.

Authors

Gustavo Campos Ramos¹, Michael Hudecek²

Affiliations

¹ Department of Internal Medicine I, University Hospital Würzburg, and Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, Germany. Electronic address: Ramos_G@ukw.de.
² Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.

PMID: 35590210
DOI: 10.1016/j.medj.2022.01.012

Abstract

Cell therapy with genetically engineered T cells has revolutionized the treatment of malignant diseases, but its potential use beyond the realms of oncology has been underexplored. In a recent study, Rurik et al.¹ built on the technologies underlying mRNA vaccines to transduce T cells in vivo, harnessing them to target cardiac fibrosis.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Cell Engineering
Genetic Engineering
Humans
Medical Oncology
Neoplasms*
T-Lymphocytes*